Summary
GlobalData, the industry analysis specialist's new report, "Alzheimer's Disease-Drug Pipeline Analysis and Market Forecasts to 2015" is an essential source of information and analysis on the global Alzheimer's disease market. The report identifies the key trends shaping and driving the dynamism in the global Alzheimer's disease market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global Alzheimer's disease sector.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData's team of industry experts.
Scope
The scope of the report includes:
-Annualized global Alzheimer's disease market revenues data from 2000 to 2008, forecast forward for 7 years to 2015.
-Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, and Japan.
-Pipeline analysis data providing a split across different phases, mechanism of action being developed and emerging trends. Key classes of mechanism of action include immunotherapy, NMDA agonists, acetylcholine inhibitors, gamma secretase modulators, serotonin receptor antagonists, muscarinic receptor agonists, alpha secretase enhancers, beta secretase inhibitors, tau inhibitors and non-steroidal anti-inflammatory classes of drugs.
-Analysis of the current and future market competition in the global Alzheimer's disease market. Each trend is independently researched to provide qualitative analysis of what the implications on sectors are, and how are companies responding to these trends.
-Insightful review of the future market players, key industry drivers, restraints and challenges which are likely to impact the Alzheimer's disease therapeutics market in the long run. Key future market players covered are Wyeth, Elan, Astrazeneca, Medivation and Baxter Healthcare.
-Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for future market associated with Alzheimer's disease.
Reasons to buy
The report will enhance your decision making capability in a more rapid and time sensitive manner. It will allow you to:
-Develop and design your in-licensing and out-licensing strategies through review of pipeline products and technologies and by identifying companies with the most robust pipeline.
-Develop business strategies by understanding the trends shaping and driving the global Alzheimer's disease market.
-Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global Alzheimer's disease market in future.
-L2Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
-Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
-Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
-What's the next big thing in the global Alzheimer's disease market landscape?-Identify, understand and capitalize.
Table of Contents
1 Table of contents
1.1 List of Tables
1.2 List of Figures
2 Alzheimer's Disease Market: Market Characterization
2.1 Overview
2.2 Alzheimer's Disease Market Size
2.3 Alzheimer's Disease Market Forecast and CAGR
2.4 Drivers and Barriers for Alzheimer's Disease Market
2.4.1 Drivers for Alzheimer's Disease Market
2.4.2 Barriers for Alzheimer's Disease Market
2.5 Opportunity and Unmet Need
2.6 Key Takeaway
3 Alzheimer's Disease Market: Competitive Assessment
3.1 Overview
3.2 Strategic Competitor Assessment
3.3 Product Profile for Major Marketed Products in the Alzheimer's Disease Market
3.3.1 Aricept (donepezil hydrochloride)
3.3.2 Exelon (rivastigmine titrate)
3.3.3 Namenda (memantine hydrochloride)
3.4 Other Marketed Products for Alzheimer's Disease Market
3.4.1 Cognex
3.4.2 Razadyne (galantamine hydrobromide extended release capsules)
3.5 Key Takeaway
4 Alzheimer's Disease Market: Pipeline Assessment
4.1 Overview
4.2 Strategic Pipeline Assessment
4.2.1 Technology Trends Analytical Framework
4.3 Alzheimer's Disease Therapeutics-Promising Drugs Under Clinical Development
4.4 Molecule Profile for Promising Drugs under Clinical Development
4.4.1 Bapineuzumab
4.4.2 Gammagard
4.4.3 Dimebon
4.4.4 Seroquel
4.4.5 AL-108 (davunetide intranasal)
4.4.6 Rember (Trx0014) (methylthionium chloride)
4.5 Alzheimer's Disease Therapeutics Market-Clinical Pipeline by Mechanism of Action
4.6 Alzheimer's Disease Pipeline-Pipeline by Clinical Phases of Development
4.6.1 Alzheimer's disease Therapeutics-Regulatory and Phase III Clinical Pipeline
4.6.2 Alzheimer's Disease Therapeutics-Phase II Clinical Pipeline
4.6.3 Alzheimer's disease-Phase I Clinical Pipeline
4.6.4 Alzheimer's disease Therapeutics-Preclinical Pipeline
4.6.5 Alzheimer's disease Therapeutics-Discovery Pipeline
4.7 Discontinued/Suspended Drugs for Alzheimer's disease
4.8 Other drugs that have been discontinued are listed below
4.9 Key Takeaway
5 Alzheimer's Disease Market: Implications for Future Market Competition
6 Alzheimer's Disease Market: Future Players in Alzheimer's Disease Market
6.1 Introduction
6.2 AstraZeneca
6.2.1 Overview
6.2.2 CNS Portfolio
6.2.3 Alzheimer's disease Portfolio
6.3 Elan
6.3.1 Overview
6.3.2 CNS Portfolio
6.3.3 Alzheimer's Disease Product Portfolio
6.4 Wyeth (Pfizer)
6.4.1 Overview
6.4.2 CNS Portfolio
6.4.3 Alzheimer's Disease Product Portfolio
6.5 Medivation
6.5.1 Overview
6.5.2 CNS Portfolio
6.5.3 Alzheimer's Disease Product Portfolio
6.6 Baxter Healthcare
6.6.1 Overview
6.6.2 CNS Portfolio
6.6.3 Alzheimer's Disease Product Portfolio
7 Alzheimer's Disease Market: Appendix
7.1 Definitions
7.2 Acronyms
7.3 Research Methodology
7.3.1 Coverage
7.3.2 Secondary Research
7.3.3 Forecasting
7.3.4 Primary Research
7.3.5 Expert Panel validation
7.4 Contact Us
7.5 Disclaimer
7.6 Sources
List of Tables
1.1 List of Tables
Table 1: Global Alzheimer's Disease Therapeutics Market, Revenue Forecasts, 2000-2008
Table 2: Global Alzheimer's Disease Therapeutics Market, Revenue Forecasts, 2009-2015
Table 3: Major marketed products comparison in Alzheimer's Disease Market, 2009
Table 4: Alzheimer's Disease Therapeutics-Most Promising Drugs Under Clinical Development, 2009
Table 5: Alzheimer's Disease Therapeutics-Regulatory and Phase III Clinical Pipeline, 2009
Table 6: Alzheimer's Disease Therapeutics-Phase II Clinical Pipeline, 2009
Table 7: Alzheimer's Disease Therapeutics-Phase I Clinical Pipeline, 2009
Table 8: Alzheimer's Disease Therapeutics-Preclinical Clinical Pipeline, 2009
Table 9: Alzheimer's Disease Therapeutics-Discovery Clinical Pipeline, 2009
Table 10: List of Discontinued Drugs for Alzheimer's Disease, 2009
Table 11: Alzheimer's Disease Therapeutics-List of Other Discontinued Drugs in Pipeline, 2009
Table 12: AstraZeneca-CNS Marketed Products, 2009
Table 13: AstraZeneca-CNS Pipeline Products, 2009
Table 14: Elan-CNS Marketed Products, 2009
Table 15: Elan-CNS Pipeline Products, 2009
Table 16: Wyeth (Pfizer)-CNS Marketed Products, 2009
Table 17: Wyeth (Pfizer)-CNS Pipeline Products, 2009
Table 18: Medivation-CNS Pipeline Products, 2009
Table 19: Baxter Healthcare-CNS Marketed Products, 2009
Table 20: Baxter Healthcare-CNS Pipeline Products, 2009
List of Figures
1.2 List of Figures
Figure 1: Global Alzheimer's Disease Market Forecast 2000-15
Figure 2: Opportunity and Unmet Need, 2009
Figure 3: Strategic Competitor Assessment, 2009
Figure 4: Technology Trends Analytic Framework-Alzheimer's Disease Market, 2009
Figure 5: Technology Trends Analytic Framework-Description-Alzheimer's Disease Market, 2009
Figure 6: Alzheimer's Disease Therapeutics Market-Clinical Pipeline by Mechanism of Action, 2009
Figure 7: Alzheimer's Disease Pipeline by Phase of Clinical Development, 2009
Figure 8: Strategic Competitor Assessment in the Alzheimer's Disease Market, 2009
Figure 9: Alzheimer's Disease Therapeutics Market-Clinical Pipeline by Company, 2009
Figure 10: GlobalData Methodology
Figure 11: GlobalData Market Forecasting Model
